MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- BIOCON LIMITED (pharmaceuticals)
- BIOCON LIMITED Financial Data
Biocon Ltd Fact Sheet 
(BICN)
Here is the latest financial fact sheet of Biocon Ltd. For more details, see the Biocon Ltd quarterly results and Biocon Ltd share price and chart. For a sector overview, read our pharmaceuticals sector report.
BIOCON Price History
| % ch | % | 4.4 |
| No. of shares | m | 600.00 |
| % ch week | % | 2.4 |
| % ch 1-mth | % | -13.1 |
| % ch 12-mth | % | -17.3 |
| 52 week H/L | Rs | 718.4/509.1 |
BIOCON Financials
| No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| BIOCON EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 497 | 554 | 496 | 1,162 | 1,188 | |
| Low | Rs | 265 | 407 | 397 | 483 | 305 | |
| Sales per share (Unadj.) | Rs | 143.9 | 154.5 | 167.4 | 194.6 | 68.7 | |
| Earnings per share (Unadj.) | Rs | 20.7 | 24.9 | 30.5 | 34.4 | 7.6 | |
| Diluted earnings per share | Rs | 6.9 | 8.3 | 10.2 | 11.5 | 7.6 | |
| Cash flow per share (Unadj.) | Rs | 30.9 | 35.9 | 42.9 | 48.3 | 14.0 | |
| Dividends per share (Unadj.) | Rs | 5.00 | 5.00 | 5.00 | 1.00 | 1.00 | |
| Adj. dividends per share | Rs | 1.67 | 1.67 | 1.67 | 0.33 | 1.00 | |
| Dividend yield (eoy) | % | 1.3 | 1.0 | 1.1 | 0.1 | 0.1 | |
| Book value per share (Unadj.) | Rs | 151.3 | 163.1 | 201.7 | 241.9 | 86.3 | |
| Adj. book value per share | Rs | 50.4 | 54.4 | 67.2 | 80.6 | 86.3 | |
| Shares outstanding (eoy) | m | 200.00 | 200.00 | 200.00 | 200.00 | 600.00 | |
| Bonus/Rights/Conversions | - | - | - | - | IS | ||
| Price / Sales ratio | x | 2.6 | 3.1 | 2.7 | 4.2 | 10.9 | |
| Avg P/E ratio | x | 18.4 | 19.3 | 14.6 | 23.9 | 98.9 | |
| P/CF ratio (eoy) | x | 12.3 | 13.4 | 10.4 | 17.0 | 53.4 | |
| Price / Book Value ratio | x | 2.5 | 2.9 | 2.2 | 3.4 | 8.6 | |
| Dividend payout | % | 24.2 | 20.1 | 16.4 | 2.9 | 13.2 | |
| Avg Mkt Cap | Rs m | 76,190 | 96,080 | 89,220 | 164,440 | 447,900 | |
| No. of employees | `000 | 7.3 | 7.5 | 4.4 | 9.2 | 6.1 | |
| Total wages/salary | Rs m | 4,663 | 5,334 | 6,101 | 7,470 | 9,311 | |
| Avg. sales/employee | Rs Th | 3,936.1 | 4,119.7 | 7,581.9 | 4,213.9 | 6,705.8 | |
| Avg. wages/employee | Rs Th | 637.9 | 711.2 | 1,381.9 | 809.0 | 1,514.2 | |
| Avg. net profit/employee | Rs Th | 566.1 | 663.2 | 1,379.6 | 745.2 | 736.9 | |
| BIOCON INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 28,773 | 30,898 | 33,474 | 38,911 | 41,234 | |
| Other income | Rs m | 559 | 531 | 792 | 1,571 | 2,062 | |
| Total revenues | Rs m | 29,332 | 31,429 | 34,266 | 40,482 | 43,296 | |
| Gross profit | Rs m | 6,871 | 6,958 | 7,678 | 9,795 | 8,291 | |
| Depreciation | Rs m | 2,036 | 2,210 | 2,487 | 2,772 | 3,851 | |
| Interest | Rs m | 17 | 89 | 293 | 260 | 615 | |
| Profit before tax | Rs m | 5,377 | 5,190 | 5,690 | 8,334 | 5,887 | |
| Minority Interest | Rs m | -170 | -310 | 217 | 163 | 213 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 1,051 | 1,606 | 0 | 0 | |
| Tax | Rs m | 1,069 | 957 | 1,422 | 1,616 | 1,569 | |
| Profit after tax | Rs m | 4,138 | 4,974 | 6,091 | 6,881 | 4,531 | |
| Gross profit margin | % | 23.9 | 22.5 | 22.9 | 25.2 | 20.1 | |
| Effective tax rate | % | 19.9 | 18.4 | 25.0 | 19.4 | 26.7 | |
| Net profit margin | % | 14.4 | 16.1 | 18.2 | 17.7 | 11.0 | |
| BIOCON BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 26,388 | 24,750 | 39,709 | 40,477 | 41,486 | |
| Current liabilities | Rs m | 13,796 | 15,974 | 16,657 | 16,783 | 21,413 | |
| Net working cap to sales | % | 43.8 | 28.4 | 68.9 | 60.9 | 48.7 | |
| Current ratio | x | 1.9 | 1.5 | 2.4 | 2.4 | 1.9 | |
| Inventory Days | Days | 48 | 56 | 59 | 60 | 64 | |
| Debtors Days | Days | 76 | 81 | 78 | 83 | 94 | |
| Net fixed assets | Rs m | 27,308 | 34,169 | 40,146 | 45,073 | 50,661 | |
| Share capital | Rs m | 1,000 | 1,000 | 1,000 | 1,000 | 3,000 | |
| "Free" reserves | Rs m | 27,047 | 31,622 | 39,338 | 47,377 | 48,808 | |
| Net worth | Rs m | 30,267 | 32,622 | 40,338 | 48,377 | 51,808 | |
| Long term debt | Rs m | 6,062 | 7,671 | 20,724 | 21,082 | 17,898 | |
| Total assets | Rs m | 57,506 | 63,319 | 84,581 | 93,942 | 99,897 | |
| Interest coverage | x | 317.3 | 59.3 | 20.4 | 33.1 | 10.6 | |
| Debt to equity ratio | x | 0.2 | 0.2 | 0.5 | 0.4 | 0.3 | |
| Sales to assets ratio | x | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | |
| Return on assets | % | 7.2 | 8.0 | 7.5 | 7.6 | 5.2 | |
| Return on equity | % | 13.7 | 15.2 | 15.1 | 14.2 | 8.7 | |
| Return on capital | % | 14.4 | 14.9 | 12.8 | 12.6 | 9.6 | |
| Exports to sales | % | 37.1 | 33.5 | 0 | 0 | 0 | |
| Imports to sales | % | 22.8 | 19.7 | 0 | 0 | 0 | |
| Exports (fob) | Rs m | 10,669 | 10,339 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 6,573 | 6,102 | 0 | 0 | 0 | |
| Fx inflow | Rs m | 10,803 | 10,993 | 11,614 | 12,988 | 12,058 | |
| Fx outflow | Rs m | 7,715 | 7,371 | 8,182 | 7,899 | 7,348 | |
| Net fx | Rs m | 3,088 | 3,622 | 3,432 | 5,089 | 4,710 | |
| BIOCON CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 5,607 | 2,107 | 3,706 | 6,400 | 6,621 | |
| From Investments | Rs m | -9,381 | -5,087 | -11,417 | -4,985 | -6,840 | |
| From Financial Activity | Rs m | 4,260 | 1,862 | 10,676 | -1,775 | -2,397 | |
| Net Cashflow | Rs m | 486 | -1,118 | 3,000 | -473 | -2,612 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Kiran Mazumdar Shaw (MD) | COMP SEC: Kiran Kumar | YEAR OF INC: 1978 | BSE CODE: 532523 | FV (Rs): 5 | DIV YIELD (%): 0.2 |
More Pharmaceuticals Company Fact Sheets: UNICHEM LAB ALKEM LABORATORIES SUVEN LIFESCIENCES DR. REDDYS LAB ALEMBIC PHARMA
Compare BIOCON With: UNICHEM LAB ALKEM LABORATORIES SUVEN LIFESCIENCES DR. REDDYS LAB ALEMBIC PHARMA
Compare BIOCON With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)
Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.
Views on news
BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)
Apr 26, 2019 | Updated on Apr 26, 2019For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)
May 14, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)
May 17, 2019A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.
What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)
May 17, 2019Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.
The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)
May 14, 2019These companies will help the Sensex more than double from current levels.
More|
| |
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON - ALEMBIC PHARMA COMPARISON
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.